Spinraza and Paleness - a phase IV clinical study of FDA data

Summary:

Paleness is reported as a side effect among people who take Spinraza (nusinersen sodium), especially for people who are female, 2-9 old, have been taking the drug for 1 - 6 months also take Allegra, and have Spinal muscular atrophy.

The phase IV clinical study analyzes which people have Paleness when taking Spinraza. It is created by eHealthMe based on reports of 7,063 people who have side effects when taking Spinraza from the FDA, and is updated regularly.

What is Spinraza?

Spinraza has active ingredients of nusinersen sodium. eHealthMe is studying from 7,063 Spinraza users. Check the latest studies of Spinraza.

What is Paleness?

Paleness (unusual lightness of skin colour) is found to be associated with 1,572 drugs and 2,116 conditions by eHealthMe. Check the latest studies of Paleness.

On Jul, 16, 2026

7,063 people reported to have side effects when taking Spinraza.
Among them, 20 people (0.28%) have Paleness.

Among these 20 people:

How long have people been on Spinraza when they have Paleness? *

What is the gender of people who have Paleness when taking Spinraza? *

female: 68.42 %
male: 31.58 %

What is the age of people who have Paleness when taking Spinraza? *

What are other drugs people take besides Spinraza? *

Atrovent: 5 people, 25.00%
Allegra: 5 people, 25.00%
Sodium Chloride: 1 person, 5.00%
Evrysdi: 1 person, 5.00%
Captopril: 1 person, 5.00%

What are other side effects people have besides Paleness? *

Oxygen Saturation Decreased: 8 people, 40.00%
High Blood Pressure: 7 people, 35.00%
Pneumonia: 7 people, 35.00%
Weight Decreased: 6 people, 30.00%
Bradycardia (abnormally slow heart action): 6 people, 30.00%
Nausea And Vomiting: 6 people, 30.00%
Hyperhidrosis (abnormally increased sweating): 6 people, 30.00%
Cardio-Respiratory Arrest (sudden dysfunction of heart and lungs): 6 people, 30.00%
Heart Rate Decreased: 6 people, 30.00%
Gastrin Secretion Disorder (gastrin is produced at excessive levels): 5 people, 25.00%

What are the existing conditions these people have? *

Spinal Muscular Atrophy (wasting of spinal muscles): 20 people, 100.00%
Respiratory Distress (difficulty in breathing): 5 people, 25.00%
Saliva Altered (changes in saliva composition): 1 person, 5.00%
Lung Disorder (lung disease): 1 person, 5.00%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 1 person, 5.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 5.00%
Constipation: 1 person, 5.00%
Blood Pressure Abnormal: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Spinraza and have Paleness?

- Check whether Paleness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Spinraza:

Spinraza (7,063 reports)

Paleness treatments and more:

Paleness (34,670 reports)

Browse all side effects of Spinraza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Paleness:

Paleness (1,572 drugs)

Browse all the conditions that are associated with Paleness:

Paleness (2,116 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nusinersen sodium (the active ingredients of Spinraza) and Spinraza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.